Tenaya Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports corporate governance changes at Tenaya Therapeutics, a Delaware corporation whose common stock trades on Nasdaq under the symbol TNYA. The earliest reported event occurred on December 5, 2022; the filing was signed December 7, 2022.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance information.
Material Changes
- Eli Casdin voluntarily resigned as a director and as a member of the Audit Committee effective December 5, 2022.
- The resignation did not result from any disagreement with the company or its Board of Directors.
- The Board appointed Amy Burroughs as a Class II director for a term expiring at the 2023 annual meeting of stockholders.
Compensation, Outlook, and Risks
- Ms. Burroughs will receive the standard non-employee director compensation, including an annual cash retainer of $35,000 and an additional $7,500 annual retainer for Audit Committee service.
- She received an option to purchase 40,000 shares of common stock. The option vests monthly over 36 months, subject to continued service, with full vesting upon a change in control if she remains a non-employee director through that event.
- Ms. Burroughs also entered into the company’s standard indemnification agreement.
- The filing contains no management guidance, financial outlook, material contingency, or unusual operating item.
Important Facts for Investors to Verify
- Confirm the effective dates and committee assignments associated with Mr. Casdin’s resignation.
- Review Ms. Burroughs’ qualifications and the company’s subsequent proxy materials for additional director information.
- Review the terms of the 40,000-share option, including the applicable exercise price and plan provisions, which are not stated in the filing text.
- Review Exhibit 99.1, the December 7, 2022 press release announcing the appointment.